FIELD: biotechnology.
SUBSTANCE: invention represents a pharmaceutical composition for targeting the released phosphatidylserine (PtdS), comprising an effective amount of the polypeptide and a pharmaceutically acceptable carrier, and use of a pharmaceutical composition for treating cancer. Also, use of a pharmaceutical composition for treating viral diseases. Invention relates to recombinant proteins of Gla domain and use thereof for targeting residues of phosphatidylserine (PtdS) on cell surface, in particular those expressing high levels of PtdS, such as cells that have undergone apoptosis.
EFFECT: these proteins can be associated with both diagnostic and therapeutic loads, thus allowing to identify and treat cells that express elevated levels of PtdS.
14 cl, 8 dwg, 1 ex
| Title | Year | Author | Number |
|---|---|---|---|
| GLA DOMAINS AS TARGETING AGENTS | 2014 |
|
RU2711091C2 |
| GLA DOMAINS AS THERAPEUTIC AGENTS | 2014 |
|
RU2705786C2 |
| USEFUL LOAD DELIVERY TO STEM CELLS | 2018 |
|
RU2795155C1 |
| METHOD FOR TARGETED IMPACT ON EXOSOMES | 2018 |
|
RU2781640C2 |
| FACTOR VII CHIMERIC MOLECULES | 2010 |
|
RU2563231C2 |
| MODIFIED FACTOR VII-BASED POLYPEPTIDES AND THEREOF APPLICATION | 2008 |
|
RU2571931C2 |
| MODIFIED VITAMIN K DEPENDENT POLYPEPTIDES | 2005 |
|
RU2396347C2 |
| NEW THROMBOMODULINE FUSION PROTEINS PROVIDING DIRECTIONAL TRANSFER TO TISSUE FACTOR AS ANTICOAGULANTS | 2003 |
|
RU2320366C2 |
| COMBINED THERAPY USING INHIBITORS OF TYROSINE KINASE RECEPTORS AND INHIBITORS OF ANGIOGENESIS | 2001 |
|
RU2292904C2 |
| VERSIONS OF IL-21 | 2006 |
|
RU2412199C2 |
